Combined cytotoxic and high dose medroxyprogesterone acetate treatment for advanced breast cancer

Oestrogen sulphatase activity in hormone‐dependent and hormone‐independent breast‐cancer cells: Modulation by steroidal and non‐steroidal therapeutic agents

“…However, to date, most efforts have been directed at reducing oestrogen levels in post-menopausal women through inhibition of the aromatase rather than the sulphatase enzyme Miller, 1989;Lonning et al, 1990). As little has been published regarding the specific characteristics of the oestrogen sulphatase enzyme in hormone-dependent MCF-7 and hormoneindependent MDA-MB-231 breast-cancer cells, we have sought to investigate whether there were differences in oestrogen sulphatase activities in these ER' and ER-intact cells in culture and whether the activity of this enzyme could be modulated in both these cell types by agents currently used in the treatment of advanced breast cancer, ie., medroxyprogesterone acetate (MPA) (Becher et al, 1989), 4-hydroxyandrostenedione (4-OH-A4) , tamoxifen (Jackson and Lowery, 1987) and danazol, a possible inhibitor of the oestrogen sulphatase enzyme (Carlstrom et af,, 1984).…”

Combined effect of navelbine with medroxyprogesterone acetate against human breast carcinoma MCF-7 cells in vitro

“…Medroxyprogesterone acetate (MPA) is a synthetic progesterone derivative that has been shown to be clinically effective against advanced breast cancer as a second-line hormonal therapy after tamoxifen (Pannuti et al, 1979;Becher et al, 1989). MPA has also been shown to augment the efflcacy of combined chemotherapeutic modality for breast cancer [such as cyclophosphamide doxorubicin and 5-fluorouracil (CAF)] and to ameliorate sideeffects caused by chemotherapeutic agents (Hupperets et al, 1993;Tominaga et al, 1994), thus establishing chemohormonal therapy.…”